Profile data is unavailable for this security.
About the company
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.
- Revenue in USD (TTM)15.05bn
- Net income in USD-883.30m
- Incorporated2019
- Employees38.00k
- LocationViatris Inc1000 Mylan BoulevardCANONSBURG 15317United StatesUSA
- Phone+1 (724) 514-1800
- Fax+1 (302) 655-5049
- Websitehttps://www.viatris.com/en
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | 78.54m | 4.76bn | 8.60bn | 845.00 | 2.11 | 1.68 | 1.85 | 109.56 | 5.60 | 5.66 | 0.1007 | 7.03 | 0.019 | -- | 2.91 | 92,940.83 | 111.75 | -- | 139.09 | -- | 89.14 | -- | 5,884.92 | -- | -- | -- | 0.00 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
| Intra-Cellular Therapies Inc | 613.73m | -86.37m | 9.06bn | 610.00 | -- | 7.91 | -- | 14.76 | -0.8595 | -0.8595 | 6.10 | 10.80 | 0.6011 | 1.42 | 4.94 | 1,006,112.00 | -8.46 | -38.27 | -9.74 | -42.77 | 92.30 | -- | -14.07 | -128.42 | 7.51 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Catalent Inc | 4.42bn | -413.00m | 10.83bn | 16.90k | -- | 3.05 | 140.64 | 2.45 | -2.27 | -2.27 | 24.33 | 19.57 | 0.4482 | 4.92 | 3.27 | 261,656.80 | -4.19 | 0.0124 | -4.80 | 0.014 | 21.82 | 28.93 | -9.34 | 0.0278 | 1.93 | 0.7814 | 0.5821 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
| Biomarin Pharmaceutical Inc | 2.75bn | 322.29m | 12.09bn | 3.40k | 38.16 | 2.23 | 28.66 | 4.39 | 1.66 | 1.66 | 14.02 | 28.41 | 0.4046 | 0.5242 | 4.08 | 809,411.60 | 4.74 | 0.7116 | 5.49 | 0.8079 | 78.95 | 76.30 | 11.71 | 2.05 | 2.62 | -- | 0.099 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Incyte Corp | 4.08bn | 32.48m | 13.56bn | 2.52k | 502.97 | 4.28 | 112.30 | 3.33 | 0.14 | 0.14 | 18.79 | 16.45 | 0.715 | 4.23 | 5.76 | 1,614,842.00 | 0.5698 | 9.07 | 0.7404 | 11.02 | 93.37 | 94.97 | 0.7969 | 13.68 | 1.82 | -- | 0.01 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Royalty Pharma plc | 2.27bn | 1.15bn | 15.55bn | 89.00 | 10.32 | 2.27 | 21.68 | 6.86 | 2.56 | 2.56 | 3.80 | 11.63 | 0.1337 | -- | 72.15 | 25,460,710.00 | 10.11 | 9.57 | 13.30 | 12.42 | -- | -- | 75.64 | 67.80 | -- | -- | 0.4258 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Viatris Inc | 15.05bn | -883.30m | 15.82bn | 38.00k | -- | 0.799 | 8.29 | 1.05 | -0.7389 | -0.7389 | 12.54 | 16.58 | 0.3219 | 2.23 | 4.94 | 396,013.20 | -1.89 | 0.0887 | -2.23 | 0.1061 | 42.49 | 40.29 | -5.87 | 0.2891 | 0.9615 | 2.37 | 0.443 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Biogen Inc | 9.61bn | 1.62bn | 23.03bn | 7.57k | 14.28 | 1.40 | 10.17 | 2.40 | 11.07 | 11.07 | 65.83 | 112.90 | 0.34 | 0.8604 | 4.58 | 1,269,155.00 | 5.71 | 12.53 | 7.01 | 14.83 | 75.59 | 83.04 | 16.80 | 26.93 | 0.8039 | 4.89 | 0.2778 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 135.35m | 11.34% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 63.12m | 5.29% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 62.75m | 5.26% |
| Davis Selected Advisers LPas of 30 Sep 2024 | 62.65m | 5.25% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 47.06m | 3.94% |
| Geode Capital Management LLCas of 30 Sep 2024 | 29.44m | 2.47% |
| Invesco Capital Management LLCas of 30 Sep 2024 | 27.78m | 2.33% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2024 | 21.25m | 1.78% |
| Rubric Capital Management LPas of 30 Sep 2024 | 20.14m | 1.69% |
| Camber Capital Management LPas of 30 Sep 2024 | 15.00m | 1.26% |
